Cellosaurus logo
expasy logo

Cellosaurus UACC62R (CVCL_WU69)

[Text][XML][JSON]
Cell line name UACC62R
Accession CVCL_WU69
Resource Identification Initiative To cite this cell line use: UACC62R (RRID:CVCL_WU69)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
Omics: Transcriptomics; RNAseq.
Derived from site: In situ; Skin; UBERON=UBERON_0002097.
Sequence variations
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Pro248Thrfs*5 (c.741dupA) (c.741_742insA); ClinVar=VCV000142259; Zygosity=Homozygous (from parent cell line).
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1780 (UACC-62)
Sex of cell Sex unspecified
Age at sampling Age unspecified
Category Cancer cell line
Publications

DOI=10.1101/381806
Sean Alexander Misek, Kathryn M. Appleton, Thomas S. Dexheimer, Erika M. Lisabeth, Roger S. Lo, Scott D. Larsen, Kathleen A. Gallo, Richard R. Neubig;
Rho-mediated MRTF and YAP1 activation contributes to BRAF inhibitor resistance in Sox9High/Sox10Low melanoma cells.
bioRxiv 2018:381806-381806(2018)

Cross-references
Cell line databases/resources cancercelllines; CVCL_WU69
Encyclopedic resources Wikidata; Q98133801
Gene expression databases GEO; GSM3195613
GEO; GSM3195614
Entry history
Entry creation05-Jul-2019
Last entry update10-Apr-2025
Version number8